Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.

Gynecologic oncology - 1 Feb 2025

De Vitis Luigi A, Reyes-Baez Fiorella E, Schivardi Gabriella, Shahi Maryam, Fought Angela J, McGree Michaela E, Capasso Ilaria, Grcevich Leah, Betella Ilaria, Ghioni Mariacristina, Guerini-Rocco Elena, Aletti Giovanni D, Cliby William, Multinu Francesco, Langstraat Carrie L, Mariani Andrea, Glaser Gretchen E

Abstract excerpt

OBJECTIVE: The optimal treatment for patients with cervical stromal invasion (CSI) in endometrial cancer (EC) remains unclear. We aimed to test the prognostic role of molecular classification in EC patients with CSI. METHODS: A retrospective, multicenter review of EC patients with CSI was performed. EC cases were assigned to one of the molecular classes: POLE mutated (POLEmut), MMR deficient (MMRd), p53 abnormal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervix Uteri
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Neoplasm Invasiveness

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Poly-ADP-Ribose Binding Proteins

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 39798193
DOI: 10.1016/j.ygyno.2024.12.013

Genes

POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.PMID 39798193Read ↗

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.Semantic proximity Read ↗

The emerging role of molecular pathology in directing the systemic treatment of endometrial cancerSemantic proximity Read ↗

Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis.Semantic proximity Read ↗

Associations between molecular subtypes and high-risk pathological factors in endometrial cancer.Semantic proximity Read ↗

Pattern of recurrence of the molecular subgroups in stage I high-grade endometrial cancer.Semantic proximity Read ↗

Association of Molecular Classification with FIGO Stage and Survival Outcomes in Endometrial Cancer.Semantic proximity Read ↗

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.Semantic proximity Read ↗

The relationship between histopathological data and molecular alterations with oncological outcomes in endometrioid-type endometrial cancers and a novel POLE mutation.Semantic proximity Read ↗

Molecular Characterization and Clinical Implications of Endometrial Cancer.Semantic proximity Read ↗

Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.Semantic proximity Read ↗

Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components.Semantic proximity Read ↗

Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.